|
- Revolutionary Medicines Catalyzed by Protein Degradation | Kymera . . .
Kymera is inventing a new generation of small molecule medicines by tackling the root cause of disease with targeted protein degradation
- Pipeline - Kymera Therapeutics
Kymera’s pipeline is focused on validated disease targets where protein degradation is the best or only way to improve the standard of care
- Press Releases - Kymera Therapeutics, Inc.
WATERTOWN, Mass , June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering
- Our Company - Kymera Therapeutics
Kymera is a clinical-stage biotechnology company working to reinvent the treatment of human disease through the development of innovative, highly differentiated medicines that address critical health problems and dramatically improve patients’ lives
- Kymera Overview | Kymera Therapeutics, Inc.
Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system
- Kymera Therapeutics Announces Positive First-in-Human Results from . . .
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives
- Media - Kymera Therapeutics
Read news and insights on how Kymera is advancing a new class of small molecule medicines using targeted protein degradation
- Our Approach - Kymera Therapeutics
Kymera’s powerful drug discovery engine delivers first-in-class investigational drugs in areas with high unmet need that are primed for clinical-stage development
|
|
|